Elthera, a biotech company based in Schlieren in the canton of Zurich, and LegoChemBiosciences Inc.have signed a licensing agreement. This is for the South Korean biopharmaceutical company to acquire a monoclonal antibody developed by Elthera in clinical testing.
According to a press release, this is a monoclonal antibody with a target molecule that appears in various solid tumors, such as pancreatic, ovarian, breast, lung, and colorectal cancer. In future, LegoChemBio will develop and market products containing this antibody using its platform technology for the creation of innovative antibody-drug conjugates (ADCs).
According to the information provided, Elthera will receive an advance payment and can claim payments based on the progress of developmental, regulatory, and commercial milestones in return. Additionally, Elthera will receive license fees from net product sales.
Elthera’s CEO Anne Schmidt commented: “This agreement is the result of a fruitful collaboration with LegoChemBio, demonstrating the outstanding quality and therapeutic potential of our antibody.” She added that combining it with LegoChemBio’s antibody-drug conjugate technology creates “a well-differentiated first-in class ADC with a wide therapeutic window.” mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space